

**DATROWAY**  
**(datopotamab deruxtecan-dlnk)**

**Pre - PA Allowance**

None

---

**Prior-Approval Requirements**

**Age** 18 years of age or older

**Diagnosis**

Patient must have the following:

Unresectable or metastatic breast cancer

**AND ALL** of the following:

- a. HR-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer
- b. Patient has received endocrine-based therapy and chemotherapy
- c. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Datroway and for 7 months after the last dose
- d. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Datroway and for 4 months after the last dose

**Prior - Approval Limits**

**Quantity** 24 vials per 84 days

**Duration** 12 months

---

**Prior – Approval *Renewal* Requirements**

**Age** 18 years of age or older

**Diagnosis**

Patient must have the following:

Unresectable or metastatic breast cancer

**AND ALL** of the following:



**BlueCross  
BlueShield**

Federal Employee Program.

**DATROWAY  
(datopotamab deruxtecan-dlnk)**

- a. **NO** disease progression or unacceptable toxicity
- b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Datroway and for 7 months after the last dose
- c. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Datroway and for 4 months after the last dose

**Prior - Approval *Renewal* Limits**

Same as above